Affinity Asset Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Affinity Asset Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$677K	Hold	145,000	–	–	0.03%	106
2026 Q1	$599K	Hold	145,000	–	–	0.03%	102
2025 Q4	$580K	Buy	+145,000	New	+$527K	0.03%	92
2021 Q2	–	Sell	-2,500	Closed	-$646K	–	81
2021 Q1	$646K	Buy	+2,500	New	+$657K	0.22%	59

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Affinity Asset Advisors's XFOR Position: Q2 2026 in Review

Affinity Asset Advisors held its X4 Pharmaceuticals (XFOR) position steady in Q2 2026 at 145,000 shares worth $677K. The position accounts for 0.03% of the portfolio, ranked #106.

Affinity Asset Advisors first reported a position in XFOR in Q1 2021 and has held it in 4 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

Affinity Asset Advisors held 145,000 shares of X4 Pharmaceuticals worth $677K as of Q2 2026.
Affinity Asset Advisors left its X4 Pharmaceuticals share count unchanged in Q2 2026.
X4 Pharmaceuticals made up 0.03% of Affinity Asset Advisors's portfolio in Q2 2026, its #106 holding.
Affinity Asset Advisors first reported a position in X4 Pharmaceuticals in Q1 2021 and has held it in 4 quarters since.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.